Economic Modeling and Sensitivity Analysis

Value in Health

Volumn 1, Issue 3, 1998, Pages 187-193

  Hay, Joel W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0037863118     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.130187.x     Document Type: Conference Paper

References (7)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
2. Kannel W, Wolf P, Garrison R. The Framingham Study, Section 35: Survival Following Initial Cardiovascular Events. Bethesda, MD: National Heart, Lung and Blood Institute, 1988.
3. Hay J, Lapuerta P, Yuan Y, et al. Pravastatin cost-effectiveness for primary prevention of cardiovascular disease in the United States. Abstract 1017. American Heart Association 70th Scientific Session, Orlando, Florida. November 1997.
4. West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997;79:756-62.
5. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
7. Tonkin A (for the LIPID Study Group). Long-term intervention with pravastatin in ischaemic disease (LIPID). Late-breaking clinical trials plenary session. American Heart Association 70th Scientific Session, Orlando, Florida. November 1997.